Researchers at the University of Utah Huntsman Cancer Institute, Mountain West National Institute of Health in the US found new insights into the prognosis of triple-negative breast cancer (TNBC), an exceptionally aggressive form of the disease.
There are no reliable methods to predict recurrence of TNBC, a rare type of breast cancer, after treatments such as chemotherapy and surgery.
The study, published in the JCO Precision Oncology journal, describes a new mechanism that can predict the aggressiveness of TNBC with accuracy.
The researchers developed a patient-derived xenograft (PDX) model to assess the aggressiveness of TNBC by implanting one's tumor into a mouse and assessing its growth.
This system was more accurate than existing methods in predicting recurrence, allowing early and accurate assessment of cancer aggressiveness.
This research could have a direct impact on patient care and lead to more personalized treatment plans for patients with recurrent TNBC.
Cindy Matson, co-author of the study and head of the Breast and Gynecology Center at the Huntsman Cancer Institute, said the study has the potential to help create more customized treatment plans for individuals with recurrent triple-negative breast cancer.
Practical benefits include testing specific drugs on PDX models and providing valuable insights for physicians in treatment decisions.
"The study results are important, as tumor growth in PDX models often indicates highly aggressive cancer, making it difficult to treat in most cases," the authors said.
There are no reliable methods to predict recurrence of TNBC, a rare type of breast cancer, after treatments such as chemotherapy and surgery.
The study, published in the JCO Precision Oncology journal, describes a new mechanism that can predict the aggressiveness of TNBC with accuracy.
The researchers developed a patient-derived xenograft (PDX) model to assess the aggressiveness of TNBC by implanting one's tumor into a mouse and assessing its growth.
This system was more accurate than existing methods in predicting recurrence, allowing early and accurate assessment of cancer aggressiveness.
This research could have a direct impact on patient care and lead to more personalized treatment plans for patients with recurrent TNBC.
Cindy Matson, co-author of the study and head of the Breast and Gynecology Center at the Huntsman Cancer Institute, said the study has the potential to help create more customized treatment plans for individuals with recurrent triple-negative breast cancer.
Practical benefits include testing specific drugs on PDX models and providing valuable insights for physicians in treatment decisions.
"The study results are important, as tumor growth in PDX models often indicates highly aggressive cancer, making it difficult to treat in most cases," the authors said.
